NCT05311852

Effects of PEA-LUT on Frontal Lobe Functions and GABAergic Transmission in Long-Covid Patients

Effects of Palmitoylethanolamide Co-ultramicronized With Luteoline (Pea-lut) on Frontal Lobe Functions and GABAergic Transmission in Long Covid Patients. An 8-week Randomized Controlled Trial.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Department of Neurorehabilitation, Hospital of Vipiteno-Sterzing (BZ) Italy · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The study explore the efficacy of PEA-LUT in patients suffering from neurological symptoms of Long-Covid

Detailed description

Aim of this study was testing the possible therapeutic effects of an 8-week therapy with PEA-LUT on GABAB-ergic neurotransmission, LTP-like synaptic plasticity, indexed with transient potentiation of motor evoked potentials (MEP) amplitude after repetitive TMS given as intermittent theta burst stimulation (iTBS) in long COVID patients with cognitive complaints and fatigue.

Conditions

• Fatigue
• Cognitive Deficit
• COVID-19
• Neurophysiologic Abnormality

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	palmitoylethanolamide co-ultramicronized with antioxidant flavonoid luteolin (PEA-LUT)	assumption of the product at dosage of 700/70 mg 2 time/day for 8 weeks
DIETARY_SUPPLEMENT	Placebo	assumption of a placebo product 2 time/day for 8 weeks

Timeline

• Start date: 2021-08-16
• Primary completion: 2022-02-15
• Completion: 2022-03-15
• First posted: 2022-04-05
• Last updated: 2022-09-26

Locations

1 site across 1 country: Italy